Incubation of murine bone marrow and splenocytes with the dipeptide methyl ester, L-leucyl-L-leucine methyl ester (Leu-Leu-OMe), which results in the selective depletion of cytotoxic T cells and their precursors, natural killer cells, and monocytes, completely protected 30 recipients of fully allogeneic donor grafts from lethal graft-versus-host disease (GVHD). These results were comparable with those obtained in 30 recipients of anti-Thy 1.2 plus complement (C')-treated donor marrow. However, in contrast t o antibody-and c'-dependent T-cell depletion, which reduces the level of donor cell engraftment in our model system, we did not observe such effects using Leu-Leu-OMe marrow pretreatment. As compared with the 24 H-2 typed recipients of anti-Thy 1.2 + C'-treated donor grafts, the 29 H-2 typed recipients of Leu-Leu-OMe-treated donor grafts had significantly (P < .001) higher percentages of donor cells (mean = 93% w 74%) and significantly ( P < .00l) lower percentages of host cells (mean = 6% w 15%) posttrans-ESPITE T H E in vivo use of immunosuppressive drugs D such as methotrexate and cyclosporin A, graft-versushost disease (GVHD) remains a significant complication in bone marrow transplantation (BMT), even when the procedure is restricted to histocompatible siblings.' Removal of the GVHD-causing T-lymphocyte population from donor marrow in preclinical studies in dogs,'v8 and primates,' and in human clinical has successfully reduced the incidence and overall severity of GVHD. However, T-cell depletion (TCD), regardless of the technique, has significantly increased the incidence of graft rejection 10% to 30% in recipients of histocompatible sibling donor grafts, whereas without TCD the incidence is 0.5% to 3%.'*'@'* Although these findings may argue against TCD, more selective or less effective TCD might eliminate GVHD-causing cells without removing cells essential to the engraftment process.
without TCD the incidence is 0.5% to 3%.'*'@'* Although these findings may argue against TCD, more selective or less effective TCD might eliminate GVHD-causing cells without removing cells essential to the engraftment process.
The dipeptide methyl ester, L-leucyl-L-leucine methyl ester (Leu-Leu-OMe), is a metabolite generated by the lysosomal processing of L-leucine methyl ester by myeloid cells such as polymorphonuclear leukocytes or mononuclear phagocyte^.'^ Incorporation of Leu-Leu-OMe into cytolytic T lymphocytes (CTL) and their precursors as well as into natural killer cells (NK) and monocytes, results in cell death.l3.I4 The ability of Leu-Leu-OMe to spare cells with helper cell f~n c t i o n '~~'~ renders it effective for dissecting the role of T-cell subpopulations in GVHD and engraftment.
We have previously described a murine BMT model in which histoincompatible donor marrow is pan T-cell depleted and recipients are conditioned for BMT with 8.0 Gy of total body irradiation (TBI)." In this model, GVHD is lethal with recipient death occurring 2 to 6 weeks post-BMT. The same model can be modified to produce a varying degree of host cell repopulation by the recipient. Using this system, we found that Leu-Leu-OMe treatment of class I + class I1 major histocompatibility complex (MHC) disparate donor marrow eliminates a population of cells that mediates GVHD, similar to pan-T depletion with anti-Thy 1.2 + complement (e). Under these identical marrow pretreatment conditions, the level of donor cell chimerism was not reduced, in contrast to pan-T depletion. These results suggest that GVHD prevention may be accomplished without interfering with donor cell engraftment.
pretransplant immunosuppression and for 1 month posttransplant. Recipients were at least 8 weeks old; donors were at least 4 weeks old.
Our conditioning protocols for these strain combinations have been previously described.17 For GVHD experiments, recipients were irradiated to a total dose of 8.0 Gy using a 220 KeV x-ray source at a dose rate of 0.45 Gy/min. For engraftment experiments, recipients received 7.0 to 7.25 Gy TBI.
Our procedure has been previously described in detail.I7-l9 C57BL/6 marrow with or without splenocytes (1:l ratio) were suspended at a concentration of 20 x lo6 mL. The donor inoculum was depleted of T cells by incubation with a pan-T cell monoclonal antibody (MoAb) anti-Thy 1.2 (HO-13-4-9, American Tissue Culture Collection, [ATCC], Rockville, MD; diluted 1:25,000) for 30 minutes, at 4OC, followed by an additional 45 minutes at 37°C with low background baby rabbit C' (Pel-Freez, Rogers, AK, diluted 1:6). Marrow treated with Leu-Leu-OMe and control marrow were handled identically to anti-Thy 1.2 + C'-treated marrow except for the omission of anti-Thy 1.2. After treatment, all aliquots were washed, resuspended at lo7 cells/mL, and incubated an additional 15 minutes at room temperature. For the Leu-Leu-OMe-treated marrow only, Leu-Leu-OMe was added to a final concentration of 250 pmol/L?' At this concentration, all cytolytic and monocytic functions were eli~ninated'~.'~ (see Results). All marrow groups were then washed once in cold media and adjusted to 100 x lo6 cells/mL for GVHD experiments or 40 x lo6 cells/mL for engraftment experiments. One-half milliliter was injected into each recipient via the caudal vein. Recipients were monitored daily for survival and weight loss during the 100-day observation period.
Limiting-dilution assay (LDA) of splenocyte CTL precursor frequencies. For LDA analysis of CTL precursors, single cell suspensions of bone marrow plus spleen cells (BMS), obtained from C57BL/6 (donor strain) mice, were sham-treated, treated with 250 pmol/L Leu-Leu-OMe, or treated with anti-Thy 1.2 + C' as described above, and resuspended in supplemental Dulbecco's Modified Eagle's Media for LDA analysis as previously described.21 Various numbers of responder splenocytes were plated with lo6 irradiated (30 Gy) B1O.BR (host strain) stimulator splenocytes and 100 U recombinant murine interleukin-2 (IL-2, a generous gift of Hoffman-LaRoche, Nutley, NJ). After 8 days, each well was assayed for cytolytic activity against 5'Cr-labeled BlO.BR splenic blasts (Con A-stimulated). Wells were scored as positive if they released more 5'Cr (mean + 3 SD) than microwells containing stimulator spleen cells and IL-2, but no responder cells.
Minimal estimates of the CTL precursor frequencies were obtained from the Poisson distribution relationship between the responding cell number per culture and the logarithm of the percentage of nonresponding (negative) cultures. When plotted according to the zero-order Poisson equation, the data define a straight line with a slope equal to the frequency of CTL precursors.
In the first engraftment experiment, chimerism was assessed with complement-dependent microcytotoxicity analysis6.I7 using noncrossreactive anti-H-2 specific MoAbs (anti-H2b: clone 28-8- 
Chimerism analysis.
sity, New York, NY) were directly conjugated to fluorescein isothiocyanate (FITC) or phycoerythrin (PE), respectively, as previously described? An irrelevant mouse myeloma protein (UPC,,), mouse IgG2a; Litton Bionetics, Charleston, SC) was conjugated to FITC or PE to determine the degree of background binding. To prevent nonspecific binding by mouse macrophage and lymphocyte Fc receptors, all samples were first incubated with a saturating concentration (40 pg/mL) of an anti-Fc receptor specific MoAb (clone 2.462, generously provided by Dr Richard Hodes and Susan Sharrow, National Institutes of Health) for 15 to 30 minutes at 4°C.27 The peripheral blood mononuclear cells were then incubated with an optimal concentration of fluorochrome-labeled antibody for 45 minutes at 4OC. Cells were washed three times and resuspended for analysis. Background binding using UPC,,-FITC and UPC,,-PE was subtracted from the results obtained with the anti-H-2 specific fluorochrome-labeled antibodies, and percent donor or host cells were calculated as described.28 Zero to 1% of the control peripheral blood mononuclear cells stained positive with the irrelevant anti-H-2 antibody linked to fluorochrome, while 99% to 100% of cells were positive for the relevant anti-H-2 specific antibody linked to fluorochrome.
Peripheral blood, 150 to 250 pL, was obtained by retro-orbital venipuncture on days 7, 14, and 28 post-BMT. Leukocyte number and morphology were determined by examination of Wright-Giemsa stained slide^.^*-^' Hematocrit values were determined by capillary tube red cell to plasma volume ratios after centrifugation.
Zmmunoreconstitution studies. Immunoreconstitution was tested in mice surviving 100 days post-BMT. (1) Rejection of donor and third-party (BALB/c: H-2d) skin was tested (n = 3 mice/group). Our skin grafting procedure has been previously de~cribed.'~ (2) NK function was tested against NK sensitive YAC-1 tumor targets.I7 Percent cytotoxicity was determined at effector to target ratios of 100:1, 50:1, 25:1, and 1251. (3) CTL function was assessed as des~ribed,'~ except that lo4 P815 (H-2d) myeloma tumor target cells (NK-resistant) were substituted for YAC-1 target cells. Effector: target ratios were 50:1,25:1, 12.5:1, and 6.25:l.
Group comparisons of continuous data were made by Student's t-test. Survival data were analyzed by lifetable methods using the Mantel-Peto-Cox summary of chi square."
Hematologic evaluation of recipients post-BMT. Responders/Well bone marrow (with or without supplemental splenocytes) was used for T-cell depletion before BMT showed comparable cell yields for these groups. Taken together, the data do not show that a higher number of CTL precursors were infused in the Leu-Leu-OMe pretreated donor preparation as compared with the anti-Thy 1.2 + C-treated donor preparation.
Statistical analyses.

RESULTS
Eficacy of Leu
Eficacy of Leu-Leu-OMe treatment of bone marrow/ splenocytes in preventing GVHD induction across class Z + class II MHC barriers. To study the ability of Leu-LeuOMe to prevent GVHD, donor C57BL/6 grafts were pretreated and injected into irradiated BlO.BR recipients. The survival curves are depicted in Figs 2A (experiment 1) and 2C (experiment 2). None of the recipients of Leu-Leu-OMetreated donor cells in either experiment (n = 30) developed GVHD. In the control group receiving nontreated grafts, signs of GVHD (ruffled fur, weight loss, diarrhea, runting, alopecia) were noted between days 12 and 20 post-BMT. No control mice survived 37 days post-BMT (overall median survival = 27 days), which was significantly (P < .0001)
shorter than survival in the Leu-Leu-OMe-treated group.
Treatment of donor grafts with anti-Thy 1.2 + C' protected all but one mouse from GVHD-induced mortality. An additional four deaths occurred in this group on day 4 post-BMT, before the onset of GVHD in the control group. These early deaths were presumed to be non-GVHD related. During the entire 100-day observation period, no signs of acute or chronic GVHD (alopecia, ruffled fur, diarrhea, weight loss, leukopenia, anemia, inability to reject skin graft or mount a CTL or NK response, or increased mortality as a result of immunodeficiency disorders) appeared in either the Leu-Leu-OMe-treated or anti-Thy 1.2 + C'-treated groups. Mean weight curves also indicate that Leu-Leu-OMe or anti-Thy 1.2 + C treatment of donor grafts protected mice from GVHD. As shown in Figs 2B (experiment 1) and 2D (experiment 2), mice in the control group experienced a progressive weight loss beginning 7 to 11 days post-BMT, consistent with the onset of acute GVHD. In contrast, recipients of grafts treated with Leu-Leu-OMe or anti-Thy 1.2 + C' steadily gained weight.
20000(
We performed extensive histopathologic analysis of tissue samples including skin, liver, gastrointestinal tract, and lung and have been unable to detect subclinical GVHD in recipients of pan-T depleted marrow/splenocyte grafts in contrast to recipients of nonmanipulated marrow grafts (unpublished data). Moreover, studies varying the number of supplemental splenocytes (approximately 20% T cells) used to induce GVHD from 1 x lo5 to 25 x lo6 per mouse (n = 8/group) show a dose response in GVHD-induced mortality. As few as lo6 splenocytes (approximately 2 x lo5 T cells) caused 100% lethality by day 70 post-BMT (data not shown). Supplemental splenocytes, 1 O5 (approximately 2 x lo4 T cells), resulted in a 37.5% GVHD-induced lethality by day 70 post-BMT. Also evident in these groups of mice was a progressive weight loss beginning between days 14 through 18 in all groups.
Serotyping was performed to determine whether repopulating cells were of donor or host origin. In the first experiment, None of the control mice in either experiment survived long enough to obtain serotyping data.
Leu-Leu-OMe treatment but not anti-Thy 1.2 + C'
treatment permits donor cell engraftment to occur in recipients of H-2 disparate donor grafts. For engraftment studies, we used our previously described modifications of the C57BL/6 into BIO.BR system." Cumulative donor cell data indicate a significantly higher level of chimerism among recipients of Leu-Leu-OMetreated grafts or control grafts as compared to recipients of anti-Thy 1.2 + C'-treated grafts ( Table 1) . Percent donor cells was significantly (P < .001) lower in 24 recipients of anti-Thy 1.2 + C'-treated marrow (74 f 4) as compared with 29 recipients of Leu-Leu-OMe-treated marrow (93 f 1) or 27 controls (99 2). Although cumulative donor cell data suggest that recipients of Leu-Leu-OMe-treated grafts may have experienced slightly impaired engraftment when compared with controls, cumulative host cell data are not consistent with such an impairment. Twenty-four recipients of Leu-Leu-OMe-treated grafts had comparable host cell values (6 * 1) to those for 27 recipients of control grafts (4 + l), and values for both groups were significantly (P < .001) lower when compared with those for recipients of anti-Thy 1.2 + C'-treated grafts (15 f 2). Because these data were obtained in mice at intervals up to 2.5 months post-BMT and at two time points, we conclude that the observed differential effect of pan-T depletion and Leu-Leu- (H-2b) donors.
Methods.
percent donor cells at that time was 87%.
OMe marrow pretreatment were persistent. Analysis of individual experiments was consistent with our findings with the cumulative data. Table 2 . During the entire study period, erythroid and total leukocyte recovery in the control group and Leu-Leu-OMe-treated group and erythroid recovery (hematocrit) in all groups were not significantly different. Total leukocyte recovery in the anti-Thy 1.2 + C-treated group was consistently lower than in the other two groups. Recipients of anti-Thy 1.2 + C'-treated grafts had impaired leukocyte reconstitution, which was most evident 28 days post-BMT. These mice (n = 14) had significantly (P I .002) lower leukycyte numbers than recipients (n = 12) of Leu-Leu-OMe-treated grafts or recipients (n = 13) of control grafts. Differences in leukocyte numbers were primarily due to lymphocyte regeneration. Recipients of anti-Thy 1.2 + C-treated grafts had significantly lower (P < .001) absolute lymphocyte counts (ALC) than recipients of control grafts on day 14 and day 28 post-BMT. The ALC for recipients of Leu-Leu-OMetreated grafts was not significantly different than for controls on day 28 post-BMT, although recipients of Leu-Leu-OMetreated grafts did have a lower ALC on day 14 post-BMT. Absolute neutrophil counts (ANC) were not significantly different among the three groups a t any time point post-BMT.
Hematologic reconstitution in recipients of
Immunoreconstitution in recipients of Leu-Leu-OMetreated, anti-Thy 1.2 + C'-treated, or control marrow grafts. We measured the time to skin graft rejection of third-party grafts and the capacity of day 100 post-BMT recipients to tolerate donor skin grafts. C57BL/6 skin grafts were tolerated without evidence of scarring, retraction, or necrosis in nine recipients (n = 3 mice/group) during a 5-week observation period. In contrast, third-party grafts were rejected in all nine recipients within 14 days. No differences were noted in the speed of skin graft rejection between recipients of Leu-Leu-OMe-treated, anti-Thy 1.2 + C-treated, or control marrow grafts.
Splenic NK and CTL function was measured in mice surviving 100 days after transplantation in two experiments. Recipients of Leu-Leu-OMe-treated marrow, sham-treated marrow, or normal nontransplanted murine splenocytes had comparable NK function. (For example, at an effector: target ratio of 100:1, cytolysis averaged 73.095, 82.7%, or 80.1 %, respectively.) They also had comparable CTL function. At an effector target ratio of 50:1, specific cytolysis averaged 87.0%, 95.396, or 77.9%, respectively. Treatment of normal donor murine splenocytes with 250 pmol/L Leu-LeuOMe was effective in eliminating NK and CTL function.
DISCUSSION
We first determined whether chemical pretreatment of donor marrows/splenocytes with Leu-Leu-OMe prevented lethal GVHD observed in BlO.BR recipients of fully allogeneic C57BL/6 donor marrow grafts. Studies to date have suggested that lethal acute GVHD induced across a class I + class I1 MHC barrier is mediated mostly, but not entirely, by CDS+(Lytl +), CD4+(L3T4+), CD8-(Lyt 2-) T lymphoc y t e~. '~,~~.~' Although the CD4+ population is dominated by cells capable of proliferation and cytokine production, some CD4+ cytolytic cells are theoretically capable of mediating a donor anti-host reaction.". Since pretreatment of donor grafts with Leu-Leu-OMe eliminates multiple types of cells that mediate cytolysis regardless of cell surface phenotype, while preserving cells that produce cytokines (predominantly CD4+ with a minority of CD8+ cells), Leu-Leu-OMe treatment provides a useful method for testing the relative importance of these cell functions in both GVHD and engraftment.
Previous studies demonstrated the efficacy of 250 pmol/L Leu-Leu-OMe for preventing lethal GVHD in naive F1 (H-2d*b or H-2b,k) recipients of parental (H-2b: C57BL/6) marrow/splenocyte donor grafts.15 Furthermore, the in vitro suppressive effect of splenocytes isolated from mice undergoing GVHD across minor antigen barriers was inhibited by leucine methyl ester.36 Leucine methyl ester is converted to Leu-Leu-OMe in lysosomotropic vesicles in myeloid cells13 and is the toxic product that kills monocytes, NK, and CTL.37*38 In this study, a single brief pretreatment of fully allogeneic donor marrow/splenocyte grafts with Leu-Leu-OMe completely prevented lethal GVHD in all 30 recipients. There was no evidence of clinical or subclinical GVHD during the entire observation period of 100 days, in contrast to chronic skin GVHD previously seen in F1 recipients of parental donor grafts.20 We compared Leu-Leu-OMe pretreatment to standard C' dependent T-cell depletion using the MoAb anti-Thy 1.2. All control mice died by day 37 post-BMT in our study. The clinical appearance of murine recipients of Leu-Leu-OMe-treated grafts and murine recipients of antiThy 1.2 + C'-treated grafts was similar. However, survival was slightly lower in mice that received anti-Thy 1.2 + C-treated grafts as compared with mice that received Leu-Leu-OMe-treated grafts.
We previously reported that donor NK alone are not important to the development of GVHD in this donorrecipient strain combination;" therefore, observed efficacy of Leu-Leu-OMe treatment in GVHD prevention cannot be attributed solely to NK removal. Moreover, since removal of donor CD4+ and CD8+ cells has protected recipients of fully allogeneic bone marrow/splenocytes from lethal GVHD similarly to anti-Thy 1.2 + C',19 the efficacy of Leu-LeuOMe may result largely from the elimination of cytolytic CD4+ and CD8+ effector cells and their precursors. In vitro measurement of CTL precursors by LDA in these studies showed that Leu-Leu-OMe treatment of donor strain BMS eliminated greater than two logs of CTL precursors. The removal of CD4+ CTL or CTL precursors may explain the partial protective effect seen by our group in previous studies.'' However, the selective removal of CD8+ cells was of minimal benefit in GVHD prevention." Taken together, these data suggest that GVHD can be prevented either by The cumulative engraftment data from our studies are most consistent with a substantial reduction in chimerism resulting from anti-Thy 1.2 + C' depletion and not Leu-LeuOMe treatment or treatment with C' alone. The slight reduction in the overall percent donor cells in the Leu-LeuOMe-treated group as compared with controls was not observed in the first experiment, and may be ascribed to minor differences in the number of marrow cells infused, marrow composition, or slight variations in the in vivo myeloablation and/or immunosuppression delivered by TBI. In contrast, the reduced engraftment caused by anti-Thy 1.2 + C' was reproducible and highly significant in overall analysis. The observed differences in engraftment between anti-Thy 1.2 + C' and Leu-Leu-OMe pretreatment do not appear to be merely a reflection of a less efficient elimination of the total number of CTL precursors by the latter technique. Specifically, the number of CTL precursors infused per mouse in the recipients of Leu-Leu-OMe pretreated inocula was likely to be equal to or less than the number infused in recipients of anti-Thy 1.2 + C'-treated inocula based on both analysis of LDA data and quantiation of cell yields preand posttreatment in 11 separate BMT experiments. We favor the explanation that a true functional discrimination of the GVHD-causing cells from the engraftment promoting cells is possible by using this chemical compound, which spares helper T cells (in contrast to anti-Thy 1.2 + C' treatment) while eliminating CTL precursor cells, since (1) the allogeneic engraftment observed after Leu-Leu-OMe marrow treatment is consistent with the uninhibited in vivo bone marrow proliferation seen in a 5-day in vivo '251-5-iodo-2'-deoxyuridine incorporation assay using recipients of syngeneic donor marrow;*' and (2) published evidence also supports the feasibility of complete alloengraftment without GVHD, indicating that these processes can be dissociated in other experimental system^.^*-^' In these studies, selective TCD of syngeneic marrow administered with non-T-cell depleted fully allogeneic marrow protected mice from clinically apparent GVHD without decreasing the number of donor cells engrafted. Peripheral blood hematologic recovery among recipients of Leu-Leu-OMe-treated grafts was not different from controls except for a moderate reduction in ALC on day 14 post-BMT, which was not evident on day 28 post-BMT. In contrast, recipients of anti-Thy 1.2 + C'-treated grafts had a significant reduction in ALC on days 14 and 28 post-BMT that was largely independent of the effects of pan TCD on engraftment. Others have reported that canine recipients of autologous marrow grafts incubated with up to 4,000 pmol/L Leu-Leu-OMe had similar leukocyte recovery as compared with recipients of nonmanipulated marrow grafts.46 Taken together, these findings suggest that hematopoiesis is not adversely affected by Leu-Leu-OMe treatment a t doses that effectively prevent GVHD in mice, while anti-Thy 1.2 + C' depletion is detrimental to lymphocyte recovery.
On day 100 post-BMT, NK and CTL function, initially eliminated in the donor inoculum by Leu-Leu-OMe treatment, was restored to the level of recipients of sham-treated or normal nontransplanted controls. This supports the findings of others!'
In addition, recipients of Leu-Leu-OMetreated marrow rejected third party skin grafts and tolerated donor skin grafts. These results suggest that Leu-Leu-OMe treatment of donor marrow does not impair long-term immunoreconstitution. However, subtle defects may exist that are not detectable by these assays.
In summary, Leu-Leu-OMe treatment of donor grafts eliminates cells with a specific function independent of cell surface antigen expression. A method of GVHD prevention using Leu-Leu-OMe would have certain advantages over techniques that depend on cell surface antigen expression and lysis by MoAbs directed against specific epitopes. We recognize that there is a complex relationship between donor marrow cells and the host milieu that dictates the level of chimerism and that strategies designed to test the donor graft component alone examine only one component of the engraftment process. However, the possible differential sensitivity of GVHD-causing splenocytes and putative engraftment promoting donor cells to Leu-Leu-OMe deserves further investigation in additional animal models and strain combinations.
